WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will present at the upcoming Deutsche Bank 43rd Annual Health Care Conference. The presentation is scheduled for 8:40am ET on May 9, 2018.
A webcast of the presentation will be accessible live through the “Investors” section of the Company’s website, www.immunogen.com; a replay will be available in the same location for approximately two weeks.
About ImmunoGen, Inc.
ImmunoGen is a clinical-stage
biotechnology company that develops targeted cancer therapeutics using
its proprietary ADC technology. The Company’s lead product candidate,
mirvetuximab soravtansine, is in the Phase 3 FORWARD I trial for
FRα-positive platinum-resistant ovarian cancer, and is in the Phase 1b/2
FORWARD II trial in combination regimens for earlier-stage disease.
ImmunoGen has three additional clinical-stage product candidates, two of
which are being developed in collaboration with Jazz Pharmaceuticals.
ImmunoGen's ADC technology is also used in Roche's marketed product,
Kadcyla®, and in programs in development by Amgen, Bayer,
Biotest, CytomX, Debiopharm, Lilly, Novartis, Sanofi and Takeda. More
information about the Company can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180502006049/en/
